生技產業訊息
全面檢測新冠肺炎的方法：14天內兩次檢測抗體 — 丘福隆博士 撰作
檢測新型冠狀病毒可知：（1）病人是否為新冠肺炎患者。（2）新冠肺炎的傳播疫情。（3）採取何種有效防疫手段方不致崩解醫療體系。
全部產業訊息
-
-
View More 
Why a Tiny Colorado County Can Offer COVID-19 Tests to Every ResidentUBI集團訊息Why a Tiny Colorado County Can Offer COVID-19 Tests to Every Resident
There are advantages to having biotech executives as neighbors. -
View More 為什麼一個科羅拉多州的小縣可以讓所有居民做新冠肺炎篩檢？
-
View More 
United BioPharma Received Approval from China NMPA for a Phase 1 Trial with UB-221 in Healthy VolunteersUBI集團訊息United BioPharma Received Approval from China NMPA for a Phase 1 Trial with UB-221 in Healthy Volunteers
An Investigational New Drug (IND) application from China National Medical Products Administration (NMPA) to conduct a phase 1 clinical trial with the company’s anti-IgE UB-221 -
View More 
聯生藥抗體新藥UB-221獲中國NMPA核准進行臨床I期試驗UBI集團訊息聯生藥抗體新藥UB-221獲中國NMPA核准進行臨床I期試驗
中國國家藥品監督管理局(National Medical Products Administration，NMPA)已核准其開發中抗體新藥UB-221之I 期臨床試驗的申請 -
View More 
United BioPharma Received Approval from China NMPA for a Phase 2 Trial to Evaluate the Reduction Effect of UB-421 mAb on Latent HIV Reservoirs in ART-stabilized HIV PatientsUBI集團訊息United BioPharma Received Approval from China NMPA for a Phase 2 Trial to Evaluate the Reduction Effect of UB-421 mAb on Latent HIV Reservoirs in ART-stabilized HIV Patients
They have received Investigational New Drug (IND) approval from China National Medical Products Administration (NMPA) to conduct a Phase 2 clinical trial to evaluate UB-421’s efficacy -
View More 
中國NMPA核准聯生藥治療愛滋病抗體新藥UB-421 之一項評估減少病患HIV病毒儲存庫的臨床II期試驗申請UBI集團訊息中國NMPA核准聯生藥治療愛滋病抗體新藥UB-421 之一項評估減少病患HIV病毒儲存庫的臨床II期試驗申請
中國國家藥品監督管理局(NMPA)核准其治療HIV-1感染抗體新藥UB-421之II 期功能性治癒概念驗證臨床試驗的申請 -
View More 檢測試劑來了！美FDA授權開賣
-
View More 
聯亞生技四路並進 攻堅新冠肺炎病毒帶來的災難UBI集團訊息聯亞生技四路並進 攻堅新冠肺炎病毒帶來的災難
聯亞生技集團於3月19日受新竹科學園區管理局之邀請參加記者會，於記者會由彭文君博士代表集團發表有關COVID-19檢測試劑、疫苗及治療藥物之近期開發進度。 -
View More 
聯生藥愛滋病治療抗體新藥UB-421榮獲第十六屆國家新創獎年度續獎「新創精進獎」UBI集團訊息聯生藥愛滋病治療抗體新藥UB-421榮獲第十六屆國家新創獎年度續獎「新創精進獎」
聯合生物製藥(股)公司(聯生藥)今日宣布，其愛滋病治療抗體新藥UB-421榮獲第十六屆國家新創獎年度續獎「新創精進獎」。 -
View More 
Mei Mei Hu — TIME 100 NEXTUBI集團訊息Mei Mei Hu — TIME 100 NEXT
Even with scientists as parents, it wasn’t always obvious that Mei Mei Hu would end up as the CEO of United Neuroscience, a company she co-founded in 2014 to find new ways to fight brain diseases like Alzheimer’s. -
View More 
United BioPharma Signs clinical trial agreement with NIH/NIAID for sponsorship of a multi-drug resistant HIV trial with UB-421UBI集團訊息United BioPharma Signs clinical trial agreement with NIH/NIAID for sponsorship of a multi-drug resistant HIV trial with UB-421
The signing of a clinical trial agreement with NIH/NIAID for their sponsorship of a clinical trial with UB-421 for treatment of multi-drug resistant (MDR) HIV infection.
-
-
View More 
我們有話要說 (二)：病毒不斷突變也不怕！聯亞生技廣譜新冠疫苗可協助解決病毒變異及疫苗頻繁接種的安全與有效性！我們有話要說 (二)：病毒不斷突變也不怕！聯亞生技廣譜新冠疫苗可協助解決病毒變異及疫苗頻繁接種的安全與有效性！ -
View More 
我們有話要說 (三)：良好的保護力絕不能只看中和抗體！全球科學界大聲疾呼正視T細胞免疫記憶能力之重要性 –強力T細胞免疫才能提供免於感染各種變異病毒株的廣譜保護力–我們有話要說 (三)：良好的保護力絕不能只看中和抗體！全球科學界大聲疾呼正視T細胞免疫記憶能力之重要性 –強力T細胞免疫才能提供免於感染各種變異病毒株的廣譜保護力– -
View More 
我們有話要說(四)：聯亞生技UB-612新冠疫苗追加劑試驗數據展現強效且廣譜的的B細胞和T細胞免疫能力; 期盼政府支持UB-612加速審查，共同為國家與人民福祉創造多贏我們有話要說(四)：聯亞生技UB-612新冠疫苗追加劑試驗數據展現強效且廣譜的的B細胞和T細胞免疫能力; 期盼政府支持UB-612加速審查，共同為國家與人民福祉創造多贏
TAG相關標籤
POPULAR熱門文章
